Searchable abstracts of presentations at key conferences in endocrinology

ea0007p83 | Endocrine tumours and neoplasia | BES2004

An audit of acromegaly in North-East Scotland: increased use of medical therapy enables preservation of pituitary function

Viswanath A , Booth S , Abraham P , Bevan J

Annual reports have been provided to the UK Acromegaly Database on 72 patients seen in Aberdeen during the past decade (41 women, mean age at diagnosis 47 yrs, mean GH at diagnosis 59 mU/l and 60% with macroadenomas). Thirty percent had glucose intolerance and 33% hypertension. Fifty-eight percent underwent surgery, 36% external radiotherapy (XRT, either alone or as adjuvant therapy) and 17% primary medical therapy (PMT, 4 had declined surgery). Thirty-seven percent are curren...

ea0007p262 | Clinical case reports | BES2004

Acquired von Willebrand's disease secondary to autoimmune hypothyroidism

Viswanath A , Mayo A , King D , Bevan J

A 12-year-old girl was referred to the endocrinology clinic for investigation of short stature. She had signs of early puberty yet had precocious menstruation associated with menorrhagia. She gave a recent history of recurrent epistaxis. There was no family history of a bleeding disorder. She reported cold intolerance, dry skin and a tendency for hair to fall.On examination she was pale with no evidence of purpura or significant bruising. There was no en...

ea0029oc1.4 | Pituitary Clinical I | ICEECE2012

A multi-centre audit of the prevalence of cardiac valvulopathy in patients treated with dopamine agonists for hyperprolactinaemia

Drake W. , Stiles C. , Bevan J. , Steeds R.

Bromocriptine (BC) and cabergoline (CAB) are ergot-derived dopamine agonists (DAs) used for the treatment of hyperprolactinaemia. Recently, concern has been raised about a possible association between long-term DA use and cardiac valvular abnormalities. These concerns are largely derived from studies in patients with Parkinson’s disease receiving higher doses (typically CAB 3 mg/day vs 0.5–1 mg/week for hyperprolactinaemic patients). Studies in hyperprolactinaemic pa...

ea0009p161 | Thyroid | BES2005

The titration regimen is as effective and better tolerated than the block-replace regimen in the medical therapy of Graves' hyperthyroidism

Abraham P , Avenell A , Park C , Watson W , Bevan J

IntroductionAntithyroid drugs are widely used in the therapy of hyperthyroidism. This review (update of Cochrane review: Antithyroid drug regimen for treating Graves' hyperthyroidism. In: The Cochrane Library, Issue 4, 2003; with 4 additional trials) assesses the effects of dose, regimen and duration of antithyroid drug therapy for Graves' hyperthyroidism.MethodsThe Cochrane Controlled Trials Register, MEDLIN...

ea0009p176 | Thyroid | BES2005

Iodine deficiency goitre in the United Kingdom - the result of a vegan diet

Park C , Watson W , Bevan J , Abraham P

While iodine deficiency goitre is common worldwide, it is rarely described in the U.K. Vegan diet is the only real way for this deficiency to occur in the U.K. A MEDLINE search from 1966 revealed 1 reported case (Shaikh et al. Transient neonatal hypothyroidism due to a maternal vegan diet; Journal of Pediatric Endocrinology & Metabolism Jan 2003). We have identified 3 cases, which we will describe here.Case 1A 21-year-ol...

ea0007p130 | Growth and development | BES2004

Possible factors determining individual sensitivity to GH replacement therapy; a KIMS database analysis

Monson J , Lundberg M , Bouloux P , Bevan J , Svensson J , Koltowska-Haggstrom M , Finer N

Large databases facilitate the examination of those factors, which may determine response to treatment, potentially to develop prediction models. We have used KIMS (Pfizer's international metabolic database of GH-treated adults), to examine parameters that might predict clinical response to GH therapy in hypopituitary adults.Patients/methods: Patients with non-functioning pituitary adenoma on GH titrated to maintain serum IGF-I between minus 2 and 2 SDS,...

ea0005p44 | Clinical Case Reports | BES2003

Cyclical Cushing's syndrome associated with a pituitary gonadotrophinoma

Acharya S , Jones T , Suliman M , Park C , Watson W , Abraham P , Bevan J

Background: True cyclical Cushing's syndrome is rare and usually due to an ACTH-secreting corticotrophinoma. We describe a man with cyclical Cushing's syndrome of 15 years duration who had unexpected pituitary immunohistopathology.Clinical details: A 22-year-old man presented in 1986 with clinical features of Cushing's syndrome & urinary free cortisols up to 1800 nmol/24h, but normal low-dose DXM suppression, & normal pituitary and adrenals on CT. He was then lost ...

ea0005p193 | Reproduction | BES2003

Maternal and neonatal outcomes after conception during cabergoline therapy for hyperprolactinaemia

Booth S , Philip S , Middleton M , Park C , Abraham P , Bevan J

Background: Since receiving its UK licence in 1994, cabergoline [CAB] has become the dopamine agonist of choice for the management of hyperprolactinaemia in most UK endocrine units. Aim: To review the outcomes for the mother and neonate when CAB is taken during conception and into early gestation. Method: Retrospective review of Aberdeen casenotes from all hyperprolactinaemic women of childbearing age on CAB therapy and those of their live born infants. Results: Twenty women w...

ea0003p36 | Clinical Case Reports | BES2002

Efficacy and safety of high dose testosterone therapy in partial androgen insensitivity

Bandyopadhyay S , Watson W , Park C , Abraham P , Philip S , Acharya S , Bevan J

Efficacy and Safety of High Dose Testosterone Therapy in Partial Androgen InsensitivityS. Bandyopadhyay, W.A.Watson, C. M.Park, P. Abraham, S. Philip, S. Acharya , J.S. Bevan. Department of Endocrinology, Aberdeen Royal Infirmary, Aberdeen, AB25 2ZN.INTRODUCTION: There have been few reports of the efficacy and safety of high dose androgen therapy in men with partial androgen insensitivity (PAI). We report on the responses of a p...